Regulatory FDA taps prior knowledge to expedite cell and gene therapy development BioSpaceA year of significant policy change at the FDA brought momentum and scrutiny into the new year.Gene Therapy PlatformRead full story pharminent June 3, 2026 (Last updated: June 3, 2026) BioSpace A year of significant policy change at the FDA brought momentum and scrutiny into the new year. Gene Therapy Platform Read full story Post navigation Previous: AbbVie receives EC approval for Aquipta to treat migraineNext: Travere beefs up rare kidney disease portfolio with up to $1.1B China deal Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026